# Syncope


## guidelines:

### Key sources
The following summarized guidelines: for the evaluation and management of syncope are prepared by our editorial team based on guidelines: from the American Academy of Family Physicians (AAFP 2023), the European Society of Cardiology (ESC 2022,2021,2018,2014), the American College of Radiology (ACR 2021), the American Heart Association (AHA/HRS/ACC 2019,2018,2017), and the Canadian Pediatric Cardiology Association (CPCA/CCS 2017).

## Clinical Findings

### Symptoms
- Chest pain
- Confusion
- Fainting
- Fatigue
- Headache
- Lightheadedness
- Loss of balance
- Loss of consciousness
- Nausea
- Palpitations
- Sweating

### Past Medical History
- Cardiomyopathy
- Congenital heart disease
- Ischemic heart disease
- Stroke
- Valvular heart disease

### Triggers
- Coughing
- Micturition
- Sneezing
- Standing
- Weightlifting

## Likelihood Ratios

### Pertinent Positives
The following findings increase the probability of seizure in patients with syncope:

| Finding | LR+ | Value |
|---------|-----|-------|
| History of cut tongue | 16.70 | |
| History of head turning | 13.47 | |
| History of unusual posturing | 13.07 | |
| History of urinary incontinence | 6.53 | |
| History of central cyanosis | 5.82 | |
| History of limb jerking | 5.58 | |
| History of postictal confusion | 3.04 | |

## Studies

### 2025 • DDX-BRO
In patients presenting to the emergency department with abdominal pain, fever of unknown origin, syncope, or non-specific symptoms, CDDSS was not superior to usual care with respect to diagnostic quality risk.
**Reference:** Wolf E Hautz et al. Lancet Digit Health. 2025 Feb. [PubMed](https://pubmed.ncbi.nlm.nih.gov/39890244/)

## Screening and Diagnosis

### Diagnostic Criteria, Situational Syncope
As per ESC 2018 guidelines:
- (B): Suspect situational reflex syncope with high probability in patients with syncope occurring during or immediately after specific triggers.
- (B): Confirm reflex syncope when syncope is reproduced immediately after exercise in the presence of severe hypotension.

### Diagnostic Criteria, Vasovagal Syncope
As per ESC 2018 guidelines:
- (B): Suspect vasovagal syncope with high probability in patients with syncope precipitated by pain, fear, or standing and associated with the typical progressive prodrome (such as pallor, sweating, and/or nausea).

### Diagnostic Criteria, Carotid Sinus Syndrome
As per ESC 2018 guidelines:
- (B): Confirm carotid sinus syndrome when carotid sinus massage causes bradycardia (asystole) and/or hypotension reproducing spontaneous symptoms, and patients have clinical features compatible with a reflex mechanism of syncope.

### Diagnostic Criteria, Orthostatic Hypotension-Induced Syncope
As per ESC 2018 guidelines:
- (B): Confirm syncope due to orthostatic hypotension when syncope occurs while standing and there is concomitant significant orthostatic hypotension.
- (B): Suspect reflex syncope and orthostatic hypotension in the presence of features suggesting reflex syncope or orthostatic hypotension and the absence of features suggesting cardiac syncope.
- (B): Confirm syncope due to orthostatic hypotension when there is a fall in SBP from baseline value ≥ 20 mmHg or DBP ≥ 10 mmHg, or a decrease in SBP to < 90 mmHg reproducing spontaneous symptoms.
- (B): Suspect syncope due to orthostatic hypotension when there is an asymptomatic fall in SBP from baseline value ≥ 20 mmHg or DBP ≥ 10 mmHg or a decrease in SBP to < 90 mmHg, in the presence of symptoms (from history) consistent with orthostatic hypotension.
- (B): Suspect syncope due to orthostatic hypotension when there is a symptomatic fall in SBP from baseline value ≥ 20 mmHg or DBP ≥ 10 mmHg or a decrease in SBP to < 90 mmHg, in the presence of not all features (from history) suggestive of orthostatic hypotension.
- (C): Consider suspecting syncope due to orthostatic hypotension when there is an asymptomatic fall in SBP from baseline value ≥ 20 mmHg or DBP ≥ 10 mmHg or a decrease in SBP to < 90 mmHg, in the presence of symptoms (from history) less consistent with orthostatic hypotension.
- (B): Suspect postural orthostatic tachycardia syndrome when there is an orthostatic HR increase (> 30 bpm or > 120 bpm within 10 minutes of active standing) in the absence of orthostatic hypotension reproducing spontaneous symptoms.

### Diagnostic Criteria, Cardiac Syncope, Arrhythmic
As per ESC 2018 guidelines:
- (B): Suspect arrhythmic syncope with high probability in the presence of any of the following ECG findings:
  - persistent sinus bradycardia < 40 bpm or sinus pauses > 3 seconds in awake state and in the absence of physical training
  - mobitz II second- and third-degree AV block
  - alternating LBBB and RBBB
  - VT or rapid paroxysmal SVT
  - non-sustained episodes of polymorphic VT and long or short QT interval
  - pacemaker or implantable cardioverter defibrillator malfunction with cardiac pauses
- (B): Suspect arrhythmic syncope in the absence of syncope when periods of Mobitz II second- or third-degree AV block or a ventricular pause > 3 seconds (with the possible exception of young trained persons, during sleep or rate-controlled AF), or rapid prolonged paroxysmal SVT or VT are detected.
- (B): Confirm arrhythmic syncope when a correlation between syncope and an arrhythmia (bradyarrhythmia or tachyarrhythmia) is detected.
- (B): Confirm syncope due to second- or third-degree AV block when the AV block develops during exercise, even without syncope.

### Diagnostic Criteria, Cardiac Syncope, Structural
As per ESC 2018 guidelines:
- (B): Suspect syncope due to structural cardiopulmonary disorders with high probability when syncope presents in patients with prolapsing atrial myxoma, LA ball thrombus, severe aortic stenosis, pulmonary embolus, or acute aortic dissection.
- (B): Suspect aortic stenosis, obstructive cardiac tumors or thrombi, pericardial tamponade, and aortic dissection as the most probable causes of syncope when the ECG shows the typical features of these conditions.
- (B): Confirm cardiac ischemia-related syncope when syncope presents with evidence of acute myocardial ischemia with or without myocardial infarction.

## Classification and Risk Stratification

### Risk Assessment
As per AAFP 2023 guidelines:
- (C) Consider using risk stratification scores in the management of patients with syncope, although they have not been shown to be superior to physician judgment.

As per ESC 2018 guidelines:
- (C) Consider using risk stratification scores for risk stratification in the emergency department.

As per ACC/AHA/HRS 2017 guidelines:
- (B) Obtain evaluation of the cause and assessment for short- and long-term morbidity and mortality risk of syncope.

As per ACC/AHA/HRS 2017 guidelines:
- (C) Consider using risk stratification scores in the management of patients with syncope.

## Diagnostic Investigations

### History and Physical Examination

As per AAFP 2023 guidelines:  
- (B) Elicit history and perform a physical examination, including orthostatic BP assessment, in patients presenting with syncope.

As per ESC 2018 guidelines:
Elicit a careful history (concerning present and previous attacks, as well as eyewitness accounts, in person or through a telephone interview) and perform a physical examination (including supine and standing BP measurements) in patients with transient loss of consciousness of suspected syncopal nature.

As per ACC/AHA/HRS 2017 guidelines:
- (B) Elicit a detailed history and perform a physical examination in patients with syncope.

### Home Video Recording
As per ESC 2018 guidelines:
- (B): Encourage patients and their relatives to obtain home video recordings of spontaneous events.
- (C): Consider adding video recording to tilt testing to increase the reliability of clinical observation of induced events.
- (C): Consider obtaining tilt testing, preferably with concurrent EEG and video monitoring, for the diagnosis of psychogenic pseudosyncope.
- (C): Take into consideration the recording of spontaneous attacks with a video by an eyewitness for the diagnosis of psychogenic pseudosyncope.

### Initial ECG

As per AAFP 2023 guidelines:
- (B) Obtain an ECG in patients presenting with syncope.

As per ESC 2018 guidelines:
- (B) Obtain an initial ECG in patients with transient loss of consciousness of suspected syncopal nature.

As per ACC/AHA/HRS 2017 guidelines:
- (B) Obtain a resting 12-lead ECG as part of the initial evaluation of patients with syncope.

As per ESC 2014 guidelines:
- (B) Obtain a 12-lead ECG to identify the cause of symptoms in patients with unexplained syncope.

### Cardiac Monitoring, Noninvasive Techniques

As per ESC 2022 guidelines:
- (B) Consider obtaining ambulatory ECG monitoring to evaluate whether symptoms, including palpitations, presyncope, or syncope, are caused by ventricular arrhythmia.

As per ESC 2018 guidelines:
- (B): Obtain immediate in-hospital monitoring (in bed or by telemetry) in high-risk patients with syncope.
- (C): Consider obtaining Holter monitoring in patients having frequent syncope or presyncope (≥ 1 episode per week) episodes.
- (C): Consider placing an external loop recorder early after the index event in patients with an inter-symptom interval ≤ 4 weeks.

As per ACC/AHA/HRS 2017 guidelines:
- (B): Consider obtaining any of the following external cardiac monitoring approaches, depending on the frequency and nature of syncope events, in ambulatory patients with syncope of suspected arrhythmic etiology:
  - (C): holter monitoring
  - (C): transtelephonic monitoring
  - (C): external loop recorder
  - (C): patch recorder
  - (C): mobile cardiac outpatient telemetry
- Obtain continuous ECG monitoring in hospitalized patients admitted for syncope evaluation.

As per ESC 2021 guidelines:
  - (A): Place an implantable loop recorder for long-term ambulatory monitoring in patients with
  infrequent (< 1 per month) unexplained syncope or other symptoms suspected to be caused by bradycardia,
   if the initial comprehensive evaluation is nondiagnostic.

As per ACC/AHA/HRS 2018 guidelines,
  (C): Consider placing an implanted cardiac monitor in patients with sporadic symptoms (including
  syncope) suspected to be related to ventricular arrhythmia.

As per ESC 2018 guidelines:
  - (A): Place an implantable loop recorder in an early phase of evaluation in patients with recurrent
  syncope of uncertain origin, absence of high-risk criteria, and a high likelihood of recurrence within
  the battery life of the device.
  - (A): Place an implantable loop recorder in high-risk patients with no demonstrated cause of syncope
  after a comprehensive evaluation and not having conventional indications for primary prevention
  implantable cardioverter defibrillator or pacemaker indication.
  - (C): Consider placing an implantable loop recorder in patients with any of the following:
    - suspected or certain reflex syncope presenting with frequent or severe syncopal episodes
    - suspected epilepsy not responding to treatment
    - unexplained falls
    - recurrent episodes of unexplained syncope with systolic impairment, without a current indication
  for ICD placement

As per ACC/AHA/HRS 2017 guidelines:
  - (C): Consider placing an implantable cardiac monitor to evaluate selected ambulatory patients with
  syncope of suspected arrhythmic etiology.

### Carotid Sinus Massage

As per ESC 2021 guidelines:
  - (B): Perform carotid sinus massage in patients with syncope of unknown origin compatible with a
  reflex mechanism or with symptoms related to pressure/manipulation of the carotid sinus area, if
  carotid stenosis is ruled out.

As per ESC 2018 guidelines:
- (B): Perform carotid sinus massage in > 40 years old patients with syncope of unknown origin compatible with a reflex mechanism.
- (B): Confirm carotid sinus syndrome when carotid sinus massage causes bradycardia (asystole) and/or hypotension reproducing spontaneous symptoms, and patients have clinical features compatible with a reflex mechanism of syncope.

### Orthostatic Challenge, Active Standing
As per ESC 2018 guidelines:
- (B): Obtain intermittent BP and HR measurement by sphygmomanometer while supine and during active standing for 3 minutes for the initial evaluation of syncope.
- (C): Consider preferring continuous beat-to-beat noninvasive BP and HR measurement when short-lived BP variations are suspected, such as in initial orthostatic hypotension.
- (B): Confirm syncope due to orthostatic hypotension when syncope occurs while standing and there is concomitant significant orthostatic hypotension.
- (B): Suspect reflex syncope and orthostatic hypotension in the presence of features suggesting reflex syncope or orthostatic hypotension and the absence of features suggesting cardiac syncope.
- (B): Confirm syncope due to orthostatic hypotension when there is a fall in SBP from baseline value ≥ 20 mmHg or DBP ≥ 10 mmHg, or a decrease in SBP to < 90 mmHg reproducing spontaneous symptoms.
- (B): Suspect syncope due to orthostatic hypotension when there is an asymptomatic fall in SBP from baseline value ≥ 20 mmHg or DBP ≥ 10 mmHg or a decrease in SBP to < 90 mmHg, in the presence of symptoms (from history) consistent with orthostatic hypotension.
- (B): Suspect syncope due to orthostatic hypotension when there is a symptomatic fall in SBP from baseline value ≥ 20 mmHg or DBP ≥ 10 mmHg or a decrease in SBP to < 90 mmHg, in the presence of not all features (from history) suggestive of orthostatic hypotension.
- (C): Consider suspecting syncope due to orthostatic hypotension when there is an asymptomatic fall in SBP from baseline value ≥ 20 mmHg or DBP ≥ 10 mmHg or a decrease in SBP to < 90 mmHg, in the presence of symptoms (from history) less consistent with orthostatic hypotension.
- (B): Suspect postural orthostatic tachycardia syndrome when there is an orthostatic HR increase (> 30 bpm or > 120 bpm within 10 minutes of active standing) in the absence of orthostatic hypotension reproducing spontaneous symptoms.

As per ESC 2021 guidelines:
  - (C): Consider obtaining tilt testing in patients with suspected recurrent reflex syncope.

As per ESC 2018 guidelines:
  - (C): Consider obtaining tilt testing in patients with suspected reflex syncope, orthostatic
  hypotension, postural orthostatic tachycardia syndrome, or psychogenic pseudosyncope.
  - (C): Consider obtaining tilt testing to educate patients to recognize symptoms and learn physical
  maneuvers.
  - (C): Consider obtaining tilt testing, preferably with concurrent EEG and video monitoring, for the
  diagnosis of psychogenic pseudosyncope.
  - (B): Suspect reflex syncope, orthostatic hypotension, postural orthostatic tachycardia syndrome, or
  psychogenic pseudosyncope if tilt testing reproduces symptoms along with the characteristic circulatory
   pattern of these conditions.

As per ACC/AHA/HRS 2017 guidelines:
  - (C): Consider obtaining tilt-table testing in patients with suspected vasovagal syncope if the
  diagnosis is unclear after initial evaluation.
  - (C): Do not obtain tilt-table testing to predict response to medical treatments for vasovagal
  syncope.
  - (C): Consider obtaining tilt-table testing in patients with syncope and suspected delayed orthostatic
   hypotension if the diagnosis is unclear after initial evaluation.
  - (C): Consider obtaining tilt-table testing to distinguish convulsive syncope from epilepsy in
  selected patients.
  - (C): Consider obtaining tilt-table testing to establish a diagnosis of pseudosyncope.
  - (C): Consider obtaining simultaneous monitoring of an EEG and hemodynamic parameters during
  tilt-table testing to distinguish between syncope, pseudosyncope, and epilepsy.

### Autonomic Function Tests

As per ACC/AHA/HRS 2017 guidelines:
  - (C): Consider referring selected patients with syncope and known or suspected neurodegenerative
  disease for autonomic evaluation.

### Valsalva Maneuver

As per ESC 2018 guidelines:
  - (C): Consider performing the Valsalva maneuver to assess autonomic function in patients with
  suspected neurogenic orthostatic hypotension.
  - (C): Consider performing the Valsalva maneuver to confirm the hypotensive tendency induced by some
  forms of situational syncope, such as coughing, brass instrument playing, singing, and weightlifting.

### Deep-Breathing Test

As per ESC 2018 guidelines:
  - (B): Obtain deep-breathing tests to assess autonomic function in patients with suspected neurogenic
  orthostatic hypotension.

###  Other Tests

As per ESC 2018 guidelines:
  - (C): Consider obtaining other autonomic function tests (such as the 30:15 ratio, cold pressure test,
  sustained hand grip test, and mental arithmetic test) to assess autonomic function in patients with
  suspected neurogenic orthostatic hypotension.

### Ambulatory BP Monitoring

As per ESC 2018 guidelines:
  - (B): Obtain ambulatory BP monitoring to detect nocturnal hypertension in patients with autonomic
  failure.
  - (B): Obtain ambulatory BP monitoring to detect and monitor the degree of orthostatic hypotension and
  supine hypertension in daily life in patients with autonomic failure.
  - (C): Consider obtaining ambulatory and home BP monitoring to detect whether BP is abnormally low
  during episodes suggestive of orthostatic intolerance.

### Cardiac Imaging, Echocardiography

As per ACR 2021 guidelines:
  - (B): Obtain resting TTE as the initial imaging in patients with presyncope or syncope with clinical
  suspicion for cardiovascular etiology based on history, physical examination, and ECG findings.

As per ESC 2018 guidelines:
  - (B): Obtain echocardiography for diagnosis and risk stratification in patients with suspected
  structural heart disease.
  - (B): Obtain 2D and Doppler echocardiography during exercise in the standing, sitting, or semi-supine
  position to detect provocable LVOTO in patients with HCM, a history of syncope, and a resting or
  provoked peak instantaneous LVOT gradient < 50 mmHg.

As per ACC/AHA/HRS 2017 guidelines:
  - (D): Do not obtain routine cardiac imaging in patients with syncope unless cardiac etiology is
  suspected based on initial evaluation (including history, physical examination, or ECG).
  - (C): Consider obtaining a TTE in selected patients with suspected structural heart disease.

As per ESC 2014 guidelines:
  - (B): Obtain resting and exercise 2D and Doppler echocardiography to identify the cause of symptoms in
   patients with unexplained syncope.

### Cardiac Imaging, CT/MRI

As per ACC/AHA/HRS 2017 guidelines:
  - (C): Consider obtaining cardiac CT or MRI in selected patients presenting with syncope of suspected
  cardiac etiology.

### Exercise Stress Testing

As per AAFP 2023 guidelines:
  - (B): Obtain exercise stress testing in patients experiencing syncope during exertion.

As per ESC 2018 guidelines:
  - (B): Obtain exercise testing in patients experiencing syncope during or shortly after exertion.
  - (B): Confirm syncope due to second- or third-degree AV block when the AV block develops during
  exercise, even without syncope.
  - (B): Confirm reflex syncope when syncope is reproduced immediately after exercise in the presence of
  severe hypotension.

As per ACC/AHA/HRS 2017 guidelines:
  - (C): Consider obtaining exercise stress testing to establish the cause of syncope in selected
  patients experiencing syncope or presyncope during exertion.

As per ESC 2014 guidelines:
  - (B): Obtain upright exercise testing to identify the cause of symptoms in patients with unexplained
  syncope.

As per ACR 2021 guidelines:
  - Consider obtaining a CXR in patients with presyncope or syncope...

###  Neurological Evaluation

As per ESC 2018 guidelines:
  - (B): Obtain neurological evaluation when syncope is due to autonomic failure to evaluate the
  underlying disease.
  - (B): Obtain neurological evaluation when transient loss of consciousness is suspected to be epilepsy.
  - (B): Obtain cognitive assessment and physical performance tests in older patients with syncope or
  unexplained fall.

### Cerebrovascular Imaging

As per AAFP 2023 guidelines:
  - (D): Do not obtain neurologic imaging, including carotid ultrasound and head CT/MRI, as part of the
  evaluation for syncope in the absence of neurologic signs or symptoms.

As per ESC 2018 guidelines:
  - (D): Do not obtain neck ultrasound or brain MRI/CT in patients with syncope.
  - (B): Obtain brain MRI in patients with neurological findings indicating Parkinsonism, ataxia, or
  cognitive impairment.

As per ACC/AHA/HRS 2017 guidelines:
  - (D): Do not obtain head MRI/CT in the routine evaluation of patients with syncope without focal
  neurological findings or head injury requiring further evaluation.
  - (D): Do not obtain carotid artery imaging in the routine evaluation of patients with syncope without
  focal neurological findings on examination.

### EEG

As per ESC 2018 guidelines:
  - (D): Do not obtain an EEG in patients with syncope.
  - (C): Consider obtaining tilt testing, preferably with concurrent EEG and video monitoring, for the
  diagnosis of psychogenic pseudosyncope.

As per ACC/AHA/HRS 2017 guidelines:
  - (D): Do not obtain an EEG routinely in patients with syncope with no specific neurological features
  suggestive of a seizure.

### Laboratory Testing

As per ESC 2018 guidelines:
  - (B): Obtain testing for paraneoplastic antibodies and anti-ganglionic AChR antibodies in patients
  with acute or subacute onset of multidomain autonomic failure.

As per ACC/AHA/HRS 2017 guidelines:
  - (D): Do not obtain routine and comprehensive laboratory testing in patients with syncope.
  - (C): Consider obtaining targeted blood tests in selected patients with syncope identified based on
  clinical assessment from history, physical examination, and ECG.
  - (I): Insufficient evidence regarding the role of BNP and high-sensitivity troponin measurement in
  patients with a suspected cardiac cause of syncope.

### Genetic Testing

As per ACC/AHA/HRS 2018 guidelines:
  - (B): Obtain further evaluation for genetic arrhythmia syndromes in young patients (aged < 40 years)
  with unexplained sudden cardiac arrest, unexplained near-drowning, or recurrent exertional syncope in
  the absence of ischemic or other structural heart diseases.

## Diagnostic Procedures

###  Electrophysiological Studies

As per ESC 2022 guidelines:
  - (C): Consider obtaining electrophysiological evaluation when syncope remains unexplained after
  noninvasive evaluation in patients with dilated cardiomyopathy/hypokinetic non-dilated cardiomyopathy.

As per ESC 2021 guidelines:
  - (C): Consider obtaining electrophysiological studies in patients with syncope and bifascicular block
  when syncope remains unexplained after noninvasive evaluation or when an immediate decision about
  pacing is needed due to severity unless empirical pacemaker implantation is preferred (especially in
  elderly and frail patients).
  - (C): Consider obtaining electrophysiological studies in patients with syncope and sinus bradycardia
  when noninvasive evaluations have failed to show a correlation between syncope and bradycardia.

As per ACC/AHA/HRS 2019 guidelines:
  - (C): Consider evaluating sinus node function as part of the electrophysiology study in patients with
  symptoms suggestive of bradycardia (such as syncope, lightheadedness) undergoing an electrophysiology
  study for another indication.
  - (C): Consider obtaining an electrophysiology study in patients with symptoms suggestive of
  intermittent bradycardia (such as lightheadedness, syncope) with conduction system disease identified
  by ECG and no demonstrated AV block.

As per ACC/AHA/HRS 2018 guidelines:
  - (C): Consider obtaining electrophysiologic testing for assessing the risk of sustained VT in patients
   with ischemic or non-ischemic cardiomyopathy or adult congenital heart disease having syncope or other
   ventricular arrhythmia symptoms and not meeting indications for a primary prevention ICD.

As per ESC 2018 guidelines:
  - (B): Obtain electrophysiological studies in patients with unexplained syncope (after noninvasive
  evaluation) and previous myocardial infarction or other scar-related conditions.
  - (B): Obtain electrophysiological studies in patients with unexplained syncope and bifascicular bundle
   branch block.
  - (C): Consider obtaining electrophysiological studies in patients with syncope and asymptomatic sinus
  bradycardia if noninvasive tests (such as ECG monitoring) have failed to show a correlation between
  syncope and bradycardia.
  - (C): Consider obtaining electrophysiological studies in patients with unexplained syncope preceded by
   sudden and brief palpitations.

As per ACC/AHA/HRS 2017 guidelines:
  - (C): Consider obtaining electrophysiological studies in selected patients with syncope of suspected
  arrhythmic etiology.
  - (C): Consider obtaining electrophysiological studies in patients with moderate or severe adult
  congenital heart disease and unexplained syncope.
  - (D): Do not obtain electrophysiological studies for the evaluation of syncope in patients with normal
   ECG and normal cardiac structure and function unless an arrhythmic etiology is suspected.

### Coronary Angiography

As per ESC 2018 guidelines:
  - (C): Consider obtaining coronary angiography in patients with syncope for the same indications as in
  patients without syncope.

## Medical Management

### Setting of Care
As per AAFP 2023 guidelines:
- (B): Manage patients with low-risk features suggestive of reflex or orthostatic syncope without hospital admission.
- (B): Admit patients with high-risk features suggestive of cardiac syncope to the hospital or observation unit.

As per ESC 2018 guidelines:
- (B): Discharge patients with low-risk features, likely to have reflex syncope or situational syncope, or syncope due to orthostatic hypotension, from the emergency department.
- (B): Obtain an early intensive and prompt evaluation in a syncope unit or an emergency department observation unit (if available) or hospitalize patients with high-risk features.
- (B): Observe patients with no high- or low-risk features in the emergency department or a syncope unit.
- (C): Consider using risk stratification scores for risk stratification in the emergency department.

As per ACC/AHA/HRS 2017 guidelines:
- (C): Consider managing patients with presumptive reflex-mediated syncope without serious medical conditions in an outpatient setting.
- (C): Consider managing selected patients with suspected cardiac syncope without serious medical conditions in an outpatient setting.
- (C): Consider observing intermediate-risk patients with an unclear cause of syncope in the emergency department.
- (B): Hospitalize patients with syncope with a serious medical condition potentially relevant to the cause of syncope.

### Management of Reflex Syncope, General Principles
As per ESC 2018 guidelines:
- (B): Explain the diagnosis, provide reassurance, and explain the risk of recurrence and the avoidance of triggers and situations in all patients.
- (C): Consider modifying or discontinuing hypotensive drugs in patients with vasodepressor syncope, if possible.

### Management of Reflex Syncope, Nonpharmacological Management
As per ESC 2018 guidelines:
- (C): Consider offering isometric physical counter-pressure maneuvers in < 60 years old patients with prodromes.
- (C): Consider offering tilt training for the education of young patients.

### Management of Reflex Syncope, Pharmacotherapy
As per ESC 2018 guidelines:
- (C): Consider offering fludrocortisone in young patients with the orthostatic form of vasovagal syncope, low-normal values of arterial BP, and the absence of contraindication to the drug.
- (C): Consider offering midodrine in patients with the orthostatic form of vasovagal syncope.
- (D): Do not use β-blockers in patients with reflex syncope.

### Management of Reflex Syncope, Cardiac Pacing
As per ESC 2021 guidelines:
- (A): Perform dual-chamber pacing to reduce recurrent syncope in patients aged > 40 years, with severe, unpredictable, recurrent syncope having any of the following:
  - spontaneous documented symptomatic asystolic pauses > 3 sec or asymptomatic pauses > 6 sec due to sinus arrest or AV block
  - cardioinhibitory carotid sinus syndrome
  - asystolic syncope during tilt testing
- (C): Consider performing dual-chamber pacing to reduce syncope recurrences in patients with the clinical features of adenosine-sensitive syncope.
- (D): Do not perform cardiac pacing without a documented cardioinhibitory reflex.

As per ESC 2018 guidelines:
- (C): Consider performing cardiac pacing to reduce syncopal recurrences in > 40 years old patients with spontaneous documented symptomatic asystolic pauses > 3 seconds or asymptomatic pauses > 6 seconds due to sinus arrest, AV block, or both.
- (C): Consider performing cardiac pacing to reduce syncopal recurrences in > 40 years old patients with a tilt-induced asystolic response with recurrent frequent unpredictable syncope.
- (C): Consider performing cardiac pacing to reduce syncopal recurrences in patients with clinical features of adenosine-sensitive syncope.
- (D): Do not perform cardiac pacing in the absence of a documented cardioinhibitory reflex.

### Management of Carotid Sinus Syndrome
As per ESC 2018 guidelines:
- (C): Consider performing cardiac pacing to reduce syncopal recurrences in > 40 years old patients with cardioinhibitory carotid sinus syndrome with recurrent frequent unpredictable syncope.

As per ACC/AHA/HRS 2017 guidelines:
- (C): Consider performing permanent cardiac pacing in patients with carotid sinus syndrome (cardioinhibitory or mixed).
- (C): Consider performing dual-chamber pacing in patients with carotid sinus...

syndrome requiring permanent pacing.

### Management of Vasovagal Syncope, General Principles
As per ACC/AHA/HRS 2017 guidelines:
- (B): Educate patients with vasovagal syncope about their diagnosis and prognosis.
- (C): Consider reducing or withdrawing medications causing hypotension when appropriate in selected patients with vasovagal syncope.

### Management of Vasovagal Syncope, Nonpharmacological Management
As per ACC/AHA/HRS 2017 guidelines:
- (C): Consider offering physical counter-pressure maneuvers in patients with vasovagal syncope having a sufficiently long prodromal period.
- (I): Insufficient evidence to recommend orthostatic training in patients with frequent vasovagal syncope.
- (C): Consider encouraging increased salt and fluid intake in selected patients with vasovagal syncope unless contraindicated.

### Management of Vasovagal Syncope, Pharmacotherapy
As per ACC/AHA/HRS 2017 guidelines:
- (C): Consider offering midodrine in patients with recurrent vasovagal syncope with no history of hypertension, HF, or urinary retention.
- (C): Consider offering fludrocortisone in patients with recurrent vasovagal syncope and inadequate response to salt and fluid intake unless contraindicated.
- (C): Consider offering β-blockers in ≥ 42 years old patients with recurrent vasovagal syncope.
- (B): Offer a SSRI in patients with recurrent vasovagal syncope.

### Management of Vasovagal Syncope, Cardiac Pacing
As per ACC/AHA/HRS 2017 guidelines:
- (C) Consider performing dual-chamber pacing in selected ≥ 40 years old patients with recurrent vasovagal syncope and prolonged spontaneous pauses.

### Management of OH-Induced Syncope, General Principles
As per ESC 2018 guidelines:
- (B): Explain the diagnosis, provide reassurance, and explain the risk of recurrence and the avoidance of triggers and situations in all patients.
- (C): Consider modifying or discontinuing hypotensive drug regimens.
- (B): Advise adequate hydration and salt intake.

As per ACC/AHA/HRS 2017 guidelines:
- (B): Advise acute water ingestion for occasional, temporary relief in patients with syncope caused by neurogenic orthostatic hypotension.
- (B): Administer fluid resuscitation via PO or IV bolus in patients with syncope due to acute dehydration.
- (C): Consider encouraging increased salt and fluid intake in selected patients with neurogenic orthostatic hypotension or syncope due to dehydration.
- (C): Consider reducing or withdrawing medications causing hypotension in selected patients with syncope.

### Management of OH-Induced Syncope, Nonpharmacological Management
As per ESC 2018 guidelines:
- (C): Consider offering isometric physical counter-pressure maneuvers.
- (C): Consider offering abdominal binders and/or support stockings to reduce venous pooling.
- (C): Consider offering head-up tilt sleeping (> 10 degrees) to increase fluid volume.

As per ACC/AHA/HRS 2017 guidelines:
- (C): Consider offering physical counter-pressure maneuvers in patients with syncope due to neurogenic orthostatic hypotension.
- (C): Consider offering compression garments in patients with syncope and orthostatic hypotension.

### Management of OH-Induced Syncope, Pharmacotherapy
As per ESC 2018 guidelines:
- (C): Consider offering midodrine or fludrocortisone in patients with persisting symptoms.

As per ACC/AHA/HRS 2017 guidelines:
- (C): Consider offering midodrine, droxidopa, or fludrocortisone in patients with syncope due to neurogenic orthostatic hypotension.
- (C): Consider offering pyridostigmine in patients with syncope due to neurogenic orthostatic hypotension refractory to other treatments.
- (C): Consider offering octreotide in patients with syncope and refractory recurrent postprandial or neurogenic orthostatic hypotension.

### Management of Cardiac Arrhythmia-Induced Syncope, General Principles
As per ESC 2018 guidelines:
- (B): Manage rapid SVT or VT reproducing hypotensive or spontaneous symptoms in patients without structural heart disease with syncope preceded by sudden and brief palpitations according to current clinical practice guidelines: for ventricular arrhythmia.
- (B) (ACC/AHA/HRS 2017): Initiate guideline-directed medical therapy in patients with syncope and ventricular arrhythmia, SVT, AF, or bradycardia.

### Management of Cardiac Arrhythmia-Induced Syncope, Bradycardia
As per ESC 2021 guidelines:
- (C) Consider performing cardiac pacing to reduce recurrent episodes of syncope in patients with asymptomatic pauses > 6 sec due to sinus arrest.

As per ESC 2018 guidelines:
- (B): Perform cardiac pacing when there is an established relationship between syncope and symptomatic bradycardia due to sick sinus syndrome or intrinsic AV block.
- (B): Perform cardiac pacing in patients with intermittent/paroxysmal intrinsic third- or second-degree AV block, including AF with slow ventricular conduction.
- (C): Consider performing cardiac pacing when the relationship between syncope and asymptomatic SND is less established.
- (C): Consider placing a pacemaker in patients with syncope and asymptomatic sinus bradycardia in the presence of prolonged corrected sinus node recovery time.
- (D): Do not perform cardiac pacing in patients with reversible causes of bradycardia.

### Management of Cardiac Arrhythmia-Induced Syncope, Bundle Branch Block
As per ESC 2021 guidelines:
- (B): Perform cardiac pacing in the presence of either a baseline His-ventricular interval of ≥ 70 ms, second- or third-degree intra- or infra-Hisian block during incremental atrial pacing, or an abnormal response to pharmacological challenge in patients with unexplained syncope and bifascicular block.
- (C): Consider performing cardiac pacing in selected patients with unexplained syncope and bifascicular block without electrophysiological studies (elderly, frail patients, high-risk and/or recurrent syncope).

- (B) (ACC/AHA/HRS 2019): Perform permanent pacing in patients with syncope and bundle branch block identified to have an HV interval ≥ 70 ms or evidence of infranodal block on electrophysiological studies.

As per ESC 2018 guidelines:
- (B): Perform cardiac pacing in patients with syncope, bundle branch block, and a positive electrophysiological study or implantable loop recorder-documented AV block.
- (C): Consider performing cardiac pacing in patients with unexplained syncope and bifascicular bundle branch block.
- (B): Place a pacemaker in patients with unexplained syncope and bifascicular bundle branch block in the presence of either a baseline H-V interval of ≥ 70 ms, second- or third-degree His-Purkinje block during incremental atrial pacing, or with a pharmacological challenge.

### Management of Cardiac Arrhythmia-Induced Syncope, Long QT Syndrome
As per ESC 2022 guidelines:
- (B): Perform left cardiac sympathetic denervation in patients with symptomatic long QT syndrome experiencing syncope due to ventricular arrhythmia on β-blockers and genotype-specific drugs with an ICD.
- (C): Consider placing an ICD in patients with Andersen-Tawil syndrome with a history of unexplained syncope.

As per ESC 2018 guidelines:
- (C): Consider placing an ICD, in addition to β-blocker therapy, in patients with long QT syndrome experiencing unexplained syncope while receiving an adequate dose of β-blockers.
- (C): Consider performing left cardiac sympathetic denervation in patients with symptomatic long QT syndrome when:
  - β-blockers are not effective, not tolerated, or are contraindicated
  - ICD therapy is contraindicated or refused
  - multiple shocks on β-blocker therapy and an implanted ICD
- (C): Consider placing an implantable loop recorder instead of an ICD in patients with recurrent episodes of unexplained syncope at low risk of SCD, based on a multiparametric analysis taking into account other known risk factors for SCD.

As per ACC/AHA/HRS 2017 guidelines:
- (B): Initiate β-blocker therapy, if not contraindicated, as first-line therapy in patients with long QT syndrome and suspected arrhythmic syncope.
- (C): Consider placing an ICD in patients with long QT syndrome and suspected arrhythmic syncope on β-blocker therapy or intolerant to β-blocker therapy.
- (C): Consider performing left cardiac sympathetic denervation in patients with long QT syndrome and recurrent syncope of suspected arrhythmic mechanism failed or intolerant to β-blocker therapy.

### Management of Cardiac Arrhythmia-Induced Syncope, Short QT Syndrome
As per ESC 2022 guidelines:
- (C) Consider placing an ICD in patients with short QT syndrome and arrhythmic syncope.

As per ACC/AHA/HRS 2017 guidelines:
- (C) Consider placing an ICD in patients with short QT pattern and syncope of suspected arrhythmic etiology.

### Management of Cardiac Arrhythmia-Induced Syncope, Brugada Syndrome
As per ESC 2022 guidelines:
- (C): Consider placing an ICD in patients with type 1 Brugada pattern and an arrhythmic syncope.
- (C): Consider placing a loop recorder in patients with Brugada syndrome with unexplained syncope.

As per ACC/AHA/HRS 2018 guidelines:
- (B) Place an ICD in patients with Brugada syndrome with spontaneous type 1 Brugada ECG pattern and a recent history of syncope presumed due to ventricular arrhythmia, if the expected meaningful survival is > 1 year.

As per ESC 2018 guidelines:
- (C): Consider placing an ICD in patients with a spontaneous diagnostic type 1 ECG pattern and a history of unexplained syncope.
- (C): Consider placing an implantable loop recorder instead of an ICD in patients with recurrent episodes of unexplained syncope at low risk of SCD, based on a multiparametric analysis taking into account other known risk factors for SCD.

As per ACC/AHA/HRS 2017 guidelines:
- (C): Consider placing an ICD in patients with Brugada ECG pattern and syncope of suspected arrhythmic etiology.
- (C): Consider obtaining invasive electrophysiological studies in patients with Brugada ECG pattern and syncope of suspected arrhythmic etiology.
- (D): Do not place an ICD in patients with Brugada ECG pattern and reflex-mediated syncope without other risk factors.

## Specific Circumstances

### Pediatric Patients, Evaluation
As per ACC/AHA/HRS 2017 guidelines:
- (B): Elicit a detailed medical history and family history, perform a physical examination, and obtain a 12-lead ECG to evaluate for vasovagal syncope in all pediatric patients presenting with syncope.
- (B): Obtain noninvasive diagnostic testing in pediatric patients with syncope and suspected coronary artery disease, cardiomyopathy, or primary rhythm disorder.
- (C): Consider obtaining tilt-table testing in pediatric patients with suspected vasovagal syncope when the diagnosis is unclear.

As per CCS/CPCA 2017 guidelines:
- (B): Elicit a detailed history and perform a focused physical examination in all pediatric patients presenting with syncope.
- (B): Obtain a 12-lead ECG in all pediatric patients with atypical syncope or additional risk factors.
- (D): Avoid obtaining further cardiac investigations in pediatric patients with a history typical of vasovagal syncope, no family history of arrhythmia, and normal physical examination.
- (D): Avoid obtaining EEG or neuroimaging in pediatric patients with a history typical of vasovagal syncope, no family history of epilepsy, and normal physical examination.

### Pediatric Patients, Management
As per ACC/AHA/HRS 2017 guidelines:
- (B): Provide education on symptom awareness of prodromes along with reassurance in pediatric patients with vasovagal syncope.
- (C): Consider encouraging increased salt and fluid intake in selected pediatric patients with vasovagal syncope.
- (C): Consider offering midodrine in pediatric patients with vasovagal syncope not responding to lifestyle measures.
- (D): Do not use β-blockers in pediatric patients with vasovagal syncope.
- (I): Insufficient evidence to support the use of fludrocortisone in pediatric patients with orthostatic hypotension associated with syncope.
- (C): Consider performing cardiac pacing in pediatric patients with severe neurally mediated syncope secondary to pallid breath-holding spells.

As per CCS/CPCA 2017 guidelines:
- (B): Offer a conservative strategy, including education, avoidance of provoking factors, increased salt and fluid intake, and teaching physical maneuvers, as a preventative and rescue strategy in pediatric patients with typical vasovagal syncope.
- (B): Consider offering midodrine during active hours in pediatric patients with highly symptomatic vasovagal syncope resistant to conservative measures.
- (B): Refer pediatric patients with syncope and a history atypical for vasovagal syncope, a family history of arrhythmia or epilepsy, relevant abnormalities in physical examination, or an abnormal ECG, to a specialist with expertise in syncope.

### Elderly Patients
As per ESC 2018 guidelines:
- (B): Obtain multifactorial evaluation in older patients because more than one possible cause for syncope and unexplained fall may be present.
- (B): Obtain cognitive assessment and physical performance tests in older patients with syncope or unexplained fall.
- (C): Consider obtaining the same assessment in patients with unexplained falls as for unexplained syncope.
- (C): Consider modifying or discontinuing possible culprit medications, particularly hypotensive and psychotropic drugs, in older patients with syncope or unexplained fall.

As per ACC/AHA/HRS 2017 guidelines:
- (C): Consider providing a comprehensive approach in collaboration with an expert in geriatric care for the assessment and management of older patients with syncope.
- (C): Consider suspecting syncope as a cause of nonaccidental falls in older patients.

### Athletes
As per ACC/AHA/HRS 2017 guidelines:
- (B): Obtain cardiovascular assessment by a specialist experienced in treating athletes with syncope before resuming competitive sports.
- (C): Consider obtaining an assessment by a specialist with disease-specific expertise for athletes with syncope and high-risk markers.
- (C): Consider obtaining extended monitoring for athletes with unexplained exertional syncope after an initial cardiovascular evaluation.
- (B): Advise avoiding participation in competitive sports for athletes with syncope and phenotype-positive HCM, catecholaminergic polymorphic VT, long QT syndrome 1, or ARVC before evaluation by a specialist.

## Quality Improvement

### Driving Restrictions
As per ACC/AHA/HRS 2017 guidelines:
- (C) Consider ensuring that healthcare providers managing patients with syncope know the driving laws and restrictions in their regions and discuss implications with the patient.

## References

1. Perry M Elliott, Aris Anastasakis, Michael A Borger et al. 2014 ESC guidelines: on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014 Oct 14;35(39):2733-79. [PubMed](https://pubmed.ncbi.nlm.nih.gov/25173338/)

2. Expert Panels on Cardiac Imaging and Neurological Imaging, Seth J Kligerman, Julie Bykowski et al. ACR Appropriateness Criteria® Syncope. J Am Coll Radiol. 2021 May;18(5S):S229-S238. [PubMed](https://pubmed.ncbi.nlm.nih.gov/33958116/)

3. Michele Brignole, Angel Moya, Frederik J de Lange et al. 2018 ESC guidelines: for the diagnosis and management of syncope. Eur Heart J. 2018 Jun 1;39(21):1883-1948. [PubMed](https://pubmed.ncbi.nlm.nih.gov/29562304/)

4. Writing Committee Members, Shen WK, Sheldon RS et al. 2017 ACC / AHA / HRS guideline for the evaluation and management of patients with syncope: A report of the American College of Cardiology / American Heart Association Task Force on Clinical Practice guidelines: and the Heart Rhythm Society. Heart Rhythm. 2017 Aug;14(8):e155-e217. [PubMed](https://pubmed.ncbi.nlm.nih.gov/28286247)

5. Sana M Al-Khatib, William G Stevenson, Michael J Ackerman et al. 2017 AHA / ACC / HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology / American Heart Association Task Force on Clinical Practice guidelines: and the Heart Rhythm Society. Circulation. 2018 Sep 25;138(13):e272-e391. [PubMed](https://pubmed.ncbi.nlm.nih.gov/29084731/)

6. Max Bayard, Fereshteh Gerayli, James Holt. Syncope: Evaluation and Differential Diagnosis. Am Fam Physician. 2023 Nov;108(5):454-463. [PubMed](https://pubmed.ncbi.nlm.nih.gov/37983697/)

7. Katja Zeppenfeld, Jacob Tfelt-Hansen, Marta de Riva et al. 2022 ESC guidelines: for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022 Oct 21;43(40):3997-4126. [PubMed](https://pubmed.ncbi.nlm.nih.gov/36017572/)

8. Michael Glikson, Jens Cosedis Nielsen, Mads Brix Kronborg et al. 2021 ESC guidelines: on cardiac pacing and cardiac resynchronization therapy. Eur Heart J. 2021 Sep 14;42(35):3427-3520. [PubMed](https://pubmed.ncbi.nlm.nih.gov/34455430/)

9. Shubhayan Sanatani, Vann Chau, Anne Fournier et al. Canadian Cardiovascular Society and Canadian Pediatric Cardiology Association Position Statement on the Approach to Syncope in the Pediatric Patient. Can J Cardiol. 2017 Feb;33(2):189-198. [PubMed](https://pubmed.ncbi.nlm.nih.gov/27838109/)

10. Fred M Kusumoto, Mark H Schoenfeld, Coletta Barrett et al. 2018 ACC / AHA / HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology / American Heart Association Task Force on Clinical Practice guidelines: and the Heart Rhythm Society. Circulation. 2019 Aug 20;140(8):e382-e482. [PubMed](https://pubmed.ncbi.nlm.nih.gov/30586771/)

11. Sheldon R, Rose S, Ritchie D et al. Historical criteria that distinguish syncope from seizures. J Am Coll Cardiol. 2002 Jul 3;40(1):142-8. [PubMed](https://pubmed.ncbi.nlm.nih.gov/12103268)

12. Omar T Albassam, Robert J Redelmeier, Steven Shadowitz et al. Did This Patient Have Cardiac Syncope?: The Rational Clinical Examination Systematic Review. JAMA. 2019 Jun 25;321(24):2448-2457. [PubMed](https://pubmed.ncbi.nlm.nih.gov/31237649/)

13. Chen DK, So YT, Fisher RS et al. Use of serum prolactin in diagnosing epileptic seizures: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2005 Sep 13;65(5):668-75. [PubMed](https://pubmed.ncbi.nlm.nih.gov/16157897)

14. Hoefnagels WA, Padberg GW, Overweg J et al. Syncope or seizure? The diagnostic value of the EEG and hyperventilation test in transient loss of consciousness. J Neurol Neurosurg Psychiatry. 1991 Nov;54(11):953-6. [PubMed](https://pubmed.ncbi.nlm.nih.gov/1800665)

15. Venkatesh Thiruganasambandamoorthy, Marco L A Sivilotti, Natalie Le Sage et al. Multicenter Emergency Department Validation of the Canadian Syncope Risk Score. JAMA Intern Med. 2020 May 1;180(5):737-744. [PubMed](https://pubmed.ncbi.nlm.nih.gov/32202605/)

16. Hamid Kariman, Sepideh Harati, Saeed Safari et al. Validation of EGSYS Score in Prediction of Cardiogenic Syncope. Emerg Med Int. 2015;2015:515370. [PubMed](https://pubmed.ncbi.nlm.nih.gov/26649200/)

17. James Quinn, Daniel McDermott, Ian Stiell et al. Prospective validation of the San Francisco Syncope Rule to predict patients with serious outcomes. Ann Emerg Med. 2006 May;47(5):448-54. [PubMed](https://pubmed.ncbi.nlm.nih.gov/16631985/)

18. Furio Colivicchi, Fabrizio Ammirati, Domenico Melina et al. Development and prospective validation of a risk stratification system for patients with syncope in the emergency department: the OESIL risk score. Eur Heart J. 2003 May;24(9):811-9. [PubMed](https://pubmed.ncbi.nlm.nih.gov/12727148/)

19. Primary Writing Committee, Roopinder K Sandhu, Satish R Raj et al. Canadian Cardiovascular Society Clinical Practice Update on the Assessment and Management of Syncope. Can J Cardiol. 2020 Aug;36(8):1167-1177. [PubMed](https://pubmed.ncbi.nlm.nih.gov/32624296/)

20. Wolf E Hautz, Thimo Marcin, Stefanie C Hautz et al. Diagnoses supported by a computerised diagnostic decision support system versus conventional diagnoses in emergency patients (DDX-BRO): a multicentre, multiple-period, double-blind, cluster-randomised, crossover superiority trial. Lancet Digit Health. 2025 Feb;7(2):e136-e144. [PubMed](https://pubmed.ncbi.nlm.nih.gov/39890244/)

